Colorado Senate Bill 26-140, introduced for the 2026 Regular Session, aims to amend existing legislation by exempting specific drugs from the affordability review process managed by the Colorado Prescription Drug Affordability Board. The bill's primary objective is to alter the scope of drugs subject to cost-effectiveness and affordability assessments by the board.

This proposed legislation, if enacted, would directly impact pharmaceutical manufacturers and potentially insurers by removing certain drugs from the board's purview. Compliance officers should monitor the bill's progress through the legislative process, as its passage could alter the regulatory landscape for drug pricing and review in Colorado. No specific compliance deadlines or penalties are detailed in the current status of the bill, which is 'Under Consideration'.